 |
|
|
|
|
|
|
Tolbutamide
Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic drug sold under the brand name Orinase. This drug may be used in the management of type II diabetes if diet alone is not effective. Tolbutamide stimulates the secretion of insulin by the pancreas. Since the pancreas must synthesize insulin in order for this drug to work, it is not effective in the management of type I diabetes. It is not routinely used due to a higher incidence of adverse effects compared to newer second generation sulfonylureas, such as glyburide.
| Oral antidiabetic drugs and Insulin analogs (A10) |
|---|
| Biguanides | Metformin |
|---|
| Sulfonylureas | Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide |
|---|
| Alpha-glucosidase inhibitors | Acarbose, Miglitol, Voglibose |
|---|
| Thiazolidinediones (TZD) | Pioglitazone, Rosiglitazone, Troglitazone |
|---|
| Meglitinides | Nateglinide, Repaglinide, Mitiglinide |
|---|
| Dipeptidyl peptidase-4 (DPP-4) inhibitors | Saxagliptin, Sitagliptin, Vildagliptin |
|---|
| Glucagon-like peptide-1 analog | Exenatide |
|---|
| Insulin analogs | fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), intermediate-acting (NPH insulin), long acting (Insulin glargine, Insulin detemir) |
|---|
|
| |
|
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Tolbutamide". A list of authors is available in Wikipedia.
|
|
|
|
|
|
Top